
Moderna, Inc. company profile
$223.37−3.45%Close 13 Nov 2026
About Moderna, Inc.
Moderna is a biotechnology company focused on mRNA medicines, developing vaccines and therapeutics built on its mRNA technology platform. Its three commercial products are Spikevax and mNEXSPIKE, COVID-19 vaccines, and mRESVIA, an RSV vaccine for adults. Its pipeline spans infectious disease vaccines, oncology therapeutics and rare disease therapeutics, including candidates for seasonal influenza, a flu and COVID combination, norovirus, cytomegalovirus and Epstein-Barr virus. The company's products are sold to customers in multiple countries, and it operates a global manufacturing network with facilities in the United States, the UK, Canada and Australia. In 2025, its total revenue was $1.9 billion, largely from COVID vaccine sales.
A summary of the business section of the company's latest annual report, filed 20 Feb 2026.
Company facts
| Ticker | MRNA · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1682852 |
|---|
| Latest annual report | 10-K, filed 20 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Stéphane Bancel | Chief Executive Officer and Director | 30.7M · 7.6% | — |
|---|
| Noubar B. Afeyan, Ph.D. | Chairman | 7.1M · 1.8% | Option exercise, 21 May 2026 |
|---|
| Stephen Hoge, M.D. | President | 5.2M · 1.3% | Option exercise, 15 Oct 2026 |
|---|
| Paul Sagan | Director | 653K · < 1% | Open-market purchase, 3 Mar 2025 |
|---|
| Shannon Thyme Klinger | Chief Legal Officer | 180K · < 1% | Shares withheld for tax, 4 Sep 2026 |
|---|
| James Mock | Chief Financial Officer | 170K · < 1% | Option exercise, 5 Oct 2026 |
|---|
| François Nader, M.D. | Director | 115K · < 1% | — |
|---|
| Sandra Horning, M.D. | Director | 74.0K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Elizabeth Tallett | Director | 70.9K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Elizabeth Nabel, M.D. | Director | 38.9K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| David Rubenstein | Director | 31.5K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Abbas Hussain | Director | 30.9K · < 1% | Sale under a 10b5-1 plan, 1 May 2026 |
|---|
| Bancel Stephane | Chief Executive Officer · Director | — | Option exercise, 6 Aug 2026 |
|---|
| Nader Francois | Director | — | Option exercise, 30 Apr 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
MRNA in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.